Up­dat­ed: In­jectable form of ar­genx drug Vyv­gart fails PhI­II study in au­toim­mune platelet dis­ease

A Dutch biotech com­pa­ny that’s post­ed win af­ter win in clin­i­cal stud­ies of its au­toim­mune dis­ease drug dis­closed its first ma­jor fail­ure of the med­i­cine ear­ly Tues­day morn­ing.

Ar­genx said that a sub­cu­ta­neous ver­sion of the drug, Vyv­gart Hytru­lo, did not meet its pri­ma­ry end­point in a Phase III study of adults with pri­ma­ry im­mune throm­bo­cy­tope­nia, or ITP. It’s a sur­pris­ing set­back for the com­pa­ny, which has wooed in­vestors with plans to test the same drug in more than a dozen au­toim­mune con­di­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.